The detection of ATRT-CTCs by BCL-xL marker, which also belongs to the BCL-2 family and plays a crucial role in regulating the intrinsic pathway of apoptosis, suggests that CTC detection has the potential to monitor the recurrence of tumor subclones and to guide drug screening. This evidence concerns the gene BCL2L1 and neoplasm.